选择性磷酸二酯酶抑制剂罗氟司特在慢性阻塞性肺疾病抗炎作用的研究进展

被引：19

作者：

王瑞倩

卞涛

机构：

[1] 无锡市人民医院呼吸科

来源：

中华哮喘杂志(电子版) | 2012年 / 6卷 / 06期

关键词：

慢性阻塞性肺疾病; 磷酸二酯酶4抑制剂; 罗氟司特; 抗炎作用;

D O I：

暂无

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

100201 [内科学];

摘要：

磷酸二酯酶4(Phosphodiesterase 4,PDE4)、特异性水解环磷酸腺苷(cyclic adenosine monophosphate,cAMP),广泛存在于多种炎症细胞及结构细胞中。选择性抑制PDE4使细胞内cAMP浓度增加,呈现抗炎作用。第二代PDE4抑制剂罗氟司特(roflumilast)具有抑制中性粒细胞、T细胞、巨噬细胞等多种炎症细胞及TNF-α、LTB4、活性氧、IFN-γ等多种炎症介质的抗炎作用,成为第一个应用于慢性阻塞性肺疾病临床治疗的PDE4抑制剂。罗氟司特的抗炎效果可能与炎症类型、药物剂量、免疫形式等影响因素有关。

引用

页码：441 / 446

页数：6

共 11 条

[1]

Roflumilast N-oxide, a PDE4 inhibitor, improves cilia motility and ciliated human bronchial epithelial cells compromised by cigarette smoke in vitro [J].

Milara, J. ;

Armengot, M. ;

Banuls, P. ;

Tenor, H. ;

Beume, Rolf ;

Artigues, E. ;

Cortijo, J. .

BRITISH JOURNAL OF PHARMACOLOGY, 2012, 166 (08) :2243-2262

[2]

Roflumilast inhibits the release of chemokines and TNF-α from human lung macrophages stimulated with lipopolysaccharide [J].

Buenestado, A. ;

Grassin-Delyle, S. ;

Guitard, F. ;

Naline, E. ;

Faisy, C. ;

Israel-Biet, D. ;

Sage, E. ;

Bellamy, J. F. ;

Tenor, H. ;

Devillier, P. .

BRITISH JOURNAL OF PHARMACOLOGY, 2012, 165 (06) :1877-1890

[3]

Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD.[J].Stephen Field.Drug Design; Development and Therapy.2010, defa

[4]

The preclinical pharmacology of roflumilast – A selective; oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.[J].Armin Hatzelmann;Esteban J. Morcillo;Giuseppe Lungarella;Serge Adnot;Shahin Sanjar;Rolf Beume;Christian Schudt;Hermann Tenor.Pulmonary Pharmacology & Therapeutics.2010, 4

[5]

The Cytokine Network in Chronic Obstructive Pulmonary Disease [J].

Barnes, Peter J. .

AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2009, 41 (06) :631-638

[6]

Roflumilast: an oral, once-daily selective PDE-4 inhibitor for the management of COPD and asthma [J].

Field, Stephen K. .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2008, 17 (05) :811-818

[7]

The oral, once-daily phosphodiesterase 4 inhibitor roflumilast lacks relevant pharmacokinetic interactions with inhaled budesonide [J].

Hermann, Robert ;

Siegmund, Werner ;

Giessmann, Thomas ;

Westphal, Kristin ;

Weinbrenner, Anita ;

Hauns, Bernhard ;

Reutter, Felix ;

Lahu, Gezim ;

Bethke, Thomas D. .

JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 47 (08) :1005-1013

[8]

Roflumilast inhibition of pulmonary leukotriene production and bronchoconstriction in ovalbumin-sensitized and -challenged guinea pigs [J].

Wollin, L ;

Marx, D ;

Wohlsen, A ;

Beume, R .

JOURNAL OF ASTHMA, 2005, 42 (10) :873-878

[9]

Roflumilast; a novel; oral; selective PDE4 inhibitor; shows high absolute bioavailability.[J].M. David;K. Zech;M. Seiberling;C. Weimar;T.D. Bethke.The Journal of Allergy and Clinical Immunology.2004, 2

[10]

Cyclic nucleotide phosphodiesterases [J].

Essayan, DM .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2001, 108 (05) :671-680

← 1 2 →